Autoimmune/Inflammatory Arthritis Associated Lymphomas: Who Is at Risk?

Table 1

Studies exploring risk of lymphomas in patients with RA, SLE, Sjögren’s syndrome, inflammatory arthritis, and spondyloarthropathies.

Author	Year	Country	Disease	Population ()	Variant	RR/SIR/OR (CI)
Thomas et al. [11]	2000	Scotland	RA	17/26,623; 10/26,623	HD (SIR); NHL	3.85 (2.2, 6.2); 2.13 (1.7, 2.6)
Mariette et al. [12] (TNFI)	2011	UK	RA	18/30,000	NHL	1.07 (0.6, 1.7)
Ekström et al. [13]	2003	Sweden	RA	77/76,527; 18/30,000	HD; NHL	3.06 (2.4, 3.8); 1.89 (1.7, 2.1)
Abásolo et al. [14]	2008	Southern Europe	RA	3/789	NHL	5.4 (1.1, 15.7)
Wolfe and Michaud [15]	2004	USA	RA	4/13,869; 42/13,869	HD; NHL	3.0 (1.3, 6.8); 1.7 (1.3, 2.2)
Hemminki et al. [16]	2008	Sweden	RA	35/42,262; 280/42,262	HD; NHL	4.05 (2.8, 5.6); 2.34 (2.1, 2.6)
Anderson et al. [17]	2009	USA	RA	1157 cases/3289 controls	NHL	OR 1.2 (1.1–1.3)
Askling et al. [18]	2009	Sweden	RA	26/26,981	HD	2.7 (1.8–4.1)
Parikh-Patel et al. [19]	2009	USA	RA	325/84,475	NHL - Men,; women	2.1 (1.7, 2.5); 1.4 (1.2, 1.6)
Hellgren et al. [20]	2010	Sweden	RA	19 cases/53 controls	HD	OR 1.8 (1.0–3.0)
Chen et al. [21]	2010	Taiwan	RA	1/23,644; 59/23,644	HD; NHL	1.76 (1.5, 2.2); 3.54 (3.45, 3.63)
Mercer et al. [22]	2013	UK	RA	16/3771	NHL	3.12 (1.8, 5.1)
Dreyer et al. [23]	2013	Denmark	RA	5/3812	NHL	2.27 (0.9, 5.5)
Anderson et al. [17]	2009	USA	SS	142 cases/255 controls	NHL	1.9 (1.5–2.3)
Zhang et al. [24]	2010	China	SS	8/1320	NHL	48.1 (20.7–94.8)
Solans-Laqué et al. [25]	2011	Spain	SS	11/244	NHL	15.6 (8.7–28.2)
Weng et al. [26]	2012	Taiwan	SS	277/7852	NHL - Men; NHL- Women	3.1 (0.6–9.0); 7.1 (4.2–10.3)
Johnsen et al. [27]	2013	Norway	SS	7/443	NHL	9 (7.1–26.3)
Liang et al. [28]	2014	Meta-analysis	SS	14 studies	Lymphomas	13.8 (8.5–19.0)
Feltelius et al. [29]	2003	Sweden	AS	12/6621	Lymphomas	1.3 (0.9–1.9)
Shibata et al. [30]	2004	Japan	AS	NA/3262	Lymphomas	2.8 (1.4–5.6)
Becker et al. [31]	2005	Germany	AS	710 cases/controls	Lymphomas	3.0 (0.1–29)
Askling et al. [32]	2006	Sweden	AS	50,615 cases/92,928 controls	Lymphomas	1.0 (0.6–1.7)
Mellemkjaer et al. [33]	2008	Denmark	AS	25,941 cases/58,551 controls	Lymphomas	1.1 (0.6–1.8)
Anderson et al. [17]	2009	USA	AS	33,721 cases/122,531 controls	Lymphomas	1.1 (0.7–1.5)
Rohekar et al. [34]	2008	Canada	PsA	NA/665	Lymphomas	0.7 (0.3–1.8)
Gross et al. [35]	2014	USA	PsA	3/2977	Lymphomas	0.4 (0.1–1.2)
Nived et al. [36]	2001	Sweden	SLE	2/116	NHL	11.63 (1.40, 42.0)
Cibere et al. [37]	2001	Canada	SLE	4/297	NHL	7 (1.9, 8)
Björnådal et al. [38]	2002	Sweden	SLE	32/5715	NHL	2.86 (1.96, 4.04)
Tarr et al. [39]	2007	Hungary	SLE	2/860	NHL	3.50 (0.4, 12.5)
Parikh-Patel et al. [40]	2008	USA	SLE	96/30478	NHL	2.74 (2.22, 3.34)
Anderson et al. [17]	2009	USA	SLE	129 cases/285 controls	NHL (OR)	1.5 (1.2–1.9)
Kang et al. [41]	2010	Korea	SLE	3/914	NHL	15.4 (2.9–37.7)
Chen et al. [21]	2010	Taiwan	SLE	NA/11763	Lymphomas	7.3 (7.0–7.6)
Dreyer et al. [42]	2011	Denmark	SLE	4/576	NHL	5.0 (1.9–13.3)
Bernatsky et al. [43]	2013	Scotland	SLE	76/16409	NHL; HL	4.4 (3.5–5.5); 2.3 (0.9–4.7)
Hill et al. [44]	2001	Sweden, Denmark, and Finland	Dermatomyositis	NA/618	NHL	3.6 (1.2, 11.1)
Stockton et al. [45]	2001	Scotland	Dermatomyositis	2/50; 1/50	NHL; HL	13.3 (1.6, 48); 28.4 (0.7, 157.9)
Hill et al. [44]	2001	Sweden, Denmark, and Finland	Polymyositis	NA/914	NHL	3.7 (1.7–8.2)
Stockton et al. [45]	2001	Scotland	Polymyositis	2/40; 2/40	NHL; HL	5 (0.6, 18.1); 31 (3.8, 112)

RA: rheumatoid arthritis; SLE: systemic lupus erythematosus; AS: ankylosing spondylitis; SS: Sjögren’s syndrome; PsA: psoriatic arthritis; RR: relative risk; SIR: standardized incidence ratio; OR: odds ratio; CI: confidence interval; : number of cases of lymphoma; : study population; NA: not available.